Cantor Fitzgerald Reaffirms Their Buy Rating on NeoGenomics

By Carrie Williams

Cantor Fitzgerald analyst Bryan Brokmeier reiterated a Buy rating on NeoGenomics (NASDAQ: NEO) today and set a price target of $11. The company’s shares closed yesterday at $7.55.

According to, Brokmeier is ranked 0 out of 5 stars with an average return of -8.8% and a 45.3% success rate. Brokmeier covers the Healthcare sector, focusing on stocks such as Rosetta Genomics Ltd, Pacific Biosciences, and Laboratory Corp.

NeoGenomics has an analyst consensus of Strong Buy, with a price target consensus of $10.50.

The company has a one year high of $9.88 and a one year low of $6.90. Currently, NeoGenomics has an average volume of 373.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NeoGenomics, Inc. provides cancer diagnostics and pharma services. It operates through a network of cancer focused testing laboratories to provide genetic and molecular testing services. It offers various testing services, including Cytogenetics, Fluorescence In-Situ Hybridization, Flow Cytometry, Immunohistochemistry, Molecular testing and Pathology consultation. The company operates through one segment: Laboratory Testing Segment. The Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.